Long-term safety of ustekinumab for psoriasis

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis

(2012) Lauren Young et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

(2012) T.-F. Tsai et al.   BRITISH JOURNAL OF DERMATOLOGY

The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis

(2011) Craig Leonardi et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Reversible Posterior Leukoencephalopathy Syndrome in a Patient Treated With Ustekinumab

(2011) David Gratton   ARCHIVES OF DERMATOLOGY

Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases

(2011) Carlos G. Grijalva et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

(2011) Tsen-Fang Tsai et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

(2011) Atsuyuki IGARASHI et al.   JOURNAL OF DERMATOLOGY

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

(2011) Kenneth B. Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

(2011) David M. Pariser et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis

(2009) Erin G. Harper et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis

(2009) Antonella Di Cesare et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells

(2008) Michelle A. Lowes et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET